Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VIR-2482

Monoclonal antibody · Acts on influenza A virus hemagglutinin · developed by Vir Biotechnology

Phase 2 Most advanced trial (none active)
VIR Developer
2 Registered trials

What is VIR-2482?

VIR-2482 is an investigational agent given by intramuscular injection and studied in influenza A.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
influenza A virus hemagglutinin
Mechanism
Acts on influenza A virus hemagglutinin
Therapy area
Infectious disease
Developer
Vir Biotechnology, Inc. (VIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
V7MT9HQR2Q

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05567783 Phase 2 Influenza A Terminated VIR
NCT04033406 Phase 1 Influenza A Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza A

More from Vir Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.

Follow VIR, the company behind VIR-2482

See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.